A crystal form of a gadoteridol compound and a preparation method thereof

Through X-ray powder diffraction identification and specific preparation methods, high stability and high purity gadoterol compound crystal form B was obtained, solving the problem of insufficient crystal form stability in the prior art, and realizing drug storage and preparation development Reliability and industrial applicability.

CN114249701BActive Publication Date: 2024-11-26ANHUI POLY PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210000888.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-04
Publication Date
2024-11-26
Estimated Expiration
2042-01-04

AI Technical Summary

Technical Problem

The crystalline stability of the existing gadoterol compounds is insufficient, resulting in frequent transfusion crystal development of preparations, affecting the stability and efficacy of the drug.

Method used

The preparation method of obtaining crystal form B and crystal form A of the gadoterol compound with characteristic diffraction angle 2θ values ​​through X-ray powder diffraction, including placing and using ether and ester organic solvents for ultrasonic dissolution and vacuuming under different humidity conditions. Dry to produce crystalline forms with high purity and stability.

Benefits of technology

The high stability and reproducibility of the crystal form B of the gadoterol compound is achieved, and the transformation phenomenon in the development of preparations is avoided. It is suitable for drug storage and industrial production, which significantly improves the purification effect and dissolution performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0003454006230000021
    Figure BDA0003454006230000021
  • Figure BDA0003454006230000051
    Figure BDA0003454006230000051
Patent Text Reader

Abstract

The present invention belongs to the field of chemical medicine, and specifically relates to a crystalline form of a gadoteridol compound and a preparation method thereof, wherein the compound can be used as a contrast agent useful in diagnostic medicine. The structural formula of the gadoteridol compound is shown in Formula VI, and the crystalline form of the compound has an X-ray powder diffraction pattern of 2 θ The diffraction angles are 8.58°, 10.038°, and 10.962°, with characteristic peaks. θ The error range of the value is ±0.2°; the present invention provides a new method for preparing a gadoteridol compound crystal form, which has a significant process purification effect and is suitable for scale-up industrial production; the crystal form provided by the present invention has good stability and good reproducibility, is conducive to the storage of raw materials and preparation development, and can effectively avoid the occurrence of crystal transformation during the preparation development process.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of chemical medicine, and in particular to a crystal form of a gadoteridol compound and a preparation method thereof. The compound can be used as a contrast agent useful in diagnostic medicine. Background Art

[0002] Nuclear Magnetic Resonance Imaging (NMRI), also known as magnetic resonance imaging (MRI), has become a routine diagnostic technique in clinical medicine due to its advantages of non-invasiveness, high-resolution anatomical imaging, and non-toxicity and non-damage to living organisms. Magnetic resonance imaging is based on the relaxation of water protons in the human body from high-energy hydrogen nuclei to low-energy nuclei under external magnetic field conditions. The image quality is affected by the density and distribution of water protons in the human body. Therefore, in many cases, it is impossible to obtain clear magnetic resonance imaging anatomical images. Contrast agents can change the relaxation time of water protons around them, increase the magnetic resonance contrast between the target site and the surrounding background tissue, and thus improve the sensitivity and accuracy of MRI. Gadolinium is an extracellularly distributed, non-tissue-specific, electrically neutral, non-ionic water-soluble gadolinium-containing contrast agent with the characteristics of high relaxation time, good stability, low viscosity and permeability, etc. It is mainly filtered through the glomerulus and has low toxicity. Its high-concentration preparation has unique advantages in MRI imaging.

[0003] Crystal form is an important factor affecting the quality of drugs. When the same substance is crystallized, due to the influence of various factors, the intramolecular or intermolecular bonding mode changes, resulting in different arrangements of molecules or atoms in the lattice space and forming different crystal structures. As a result, different crystal forms may have significant differences in appearance, solubility, melting point, dissolution, storage stability, etc., thus affecting the stability, application, bioavailability and efficacy of the drug. Therefore, in order to obtain a crystal form of a gadoteridol compound with superior physiological and chemical properties so that it can advantageously meet the needs of drug production, it is necessary to conduct a comprehensive investigation of the crystallization behavior of the gadoteridol compound. Summary of the invention

[0004] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a crystalline form of a gadoteridol compound with higher stability, which is beneficial to the storage of raw materials and the development of preparations and can effectively avoid the occurrence of crystal transformation during the preparation development process.

[0005] The chemical name of the gadoteridol compound of the present invention is 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate gadolinium, and the structural formula is shown in Formula VI.

[0006]

[0007] In some embodiments, the crystalline form of the gadoteridol compound of the present invention can be identified by X-ray powder diffraction, and its X-ray powder diffraction spectrum has a diffraction angle of 2 θ The characteristic peaks are 8.58°, 10.038° and 10.962°, among which 2 θ The value error range is ±0.2°.

[0008] In a preferred embodiment, the X-ray powder diffraction spectrum of the crystalline form has a diffraction angle of 2 θ The characteristic peaks are at angles of 7.941°, 8.58°, 8.921°, 10.038°, 10.962°, 11.279°, 11.66°, and 14.099°, among which 2 θ The error range of the value is ±0.2°. For convenience, the present invention refers to Form B.

[0009] In a preferred embodiment, the X-ray powder diffraction spectrum of the crystalline form B has a diffraction angle of 2 θ The characteristic peaks further include 12.502°, 13.042°, 13.558°, 13.922°, and 17.862°, wherein 2 θ The value error range is ±0.2°.

[0010] In some embodiments, the X-ray powder diffraction spectrum of the above-mentioned Form B has a diffraction angle of 2 θ The characteristic peaks are 7.941°, 8.58°, 8.921°, 10.038°, 10.962°, 11.279°, 11.66°, 12.502°, 13.042°, 13.558°, 13.922°, 14.099°, 14.38°, 14.777°, 16.024°, 16.522°, 16.718°, 17.862°, 23.763°, 24.159°, 25.459°, 26.665°, 27.183°, and 30.804°, among which 2 θ The value error range is ±0.2°.

[0011] In some embodiments, the X-ray powder diffraction spectrum of the above-mentioned Form B has about Figure 1 The X-ray powder diffraction pattern is shown.

[0012] The present invention summarizes the X-ray powder diffraction spectrum of Form B, as shown in Table 1.

[0013] Table 1

[0014] Peak number 2θ(°) Relative strength (%) 1 7.941 79.9 2 8.58 66 3 8.921 31.1 4 10.038 53.4 5 10.962 30.2 6 11.279 100 7 11.66 65.8 8 12.502 21.5 9 13.042 15.6 10 13.558 20.1 11 13.922 19.1 12 14.099 34.4 13 14.38 10.7 14 14.777 11.3 15 16.024 15.1 16 16.522 15.6 17 16.718 10.3 18 17.862 24 19 23.763 10.6 20 24.159 10.3 21 25.459 11.7 22 26.665 13.6 23 27.183 10.6 24 30.804 11.2

[0015] Preferably, the purity of the crystalline form B is ≥95%.

[0016] Preferably, the purity of the crystalline form B is ≥99%.

[0017] Preferably, the purity of the crystalline form B is ≥99.9%.

[0018] In a preferred embodiment, the X-ray powder diffraction spectrum of the crystalline form has a diffraction angle of 2 θ The characteristic peaks are at angles of 8.6°, 10.042°, 10.958°, 12.516°, 13.057°, 13.940°, 14.083° and 14.781°, among which 2 θ The error range of the value is ±0.2°, and for convenience, the present invention refers to it as Form A.

[0019] In some embodiments, the X-ray powder diffraction spectrum of the above-mentioned crystalline form A has about Figure 2 The X-ray powder diffraction pattern is shown.

[0020] The present invention summarizes the X-ray powder diffraction spectrum of Form A, as shown in Table 2.

[0021] Table 2

[0022] Peak number 2θ(°) Relative strength (%) 1 8.6 100 2 10.042 56.1 3 10.958 10.7 4 12.516 23.5 5 13.057 17 6 13.94 19.3 7 14.083 17.5 8 14.781 10.6

[0023] Preferably, the purity of the crystalline form A is ≥95%.

[0024] Preferably, the purity of the crystalline form A is ≥99%.

[0025] Preferably, the purity of the crystalline form A is ≥99.8%.

[0026] The present invention also provides a method for preparing the crystal form A of the gadoteridol compound, comprising the following steps: adding the crude gadoteridol into a mixed solution of water and isopropanol, heating to 70-80°C and stirring, then cooling to 20-40°C, filtering the reactants, rinsing the filter cake with isopropanol, and drying in a vacuum at 30-40°C to obtain the crystal form A of the compound.

[0027] The present invention also provides a method for preparing the crystalline form B of the gadoteridol compound, comprising the following steps:

[0028] 1) Place the gadoteridol compound crystal form A at 20-40° C. and 30-90% RH for 0.5-10 days.

[0029] 2) dissolving the gadoteridol compound obtained in step 1) in a mixed organic solvent of ethers and lipids, dissolving it into a clear solution by ultrasonic treatment at 40-50° C., filtering it, stirring it at 5-10° C. to precipitate a solid, and drying it in vacuum at room temperature to obtain crystal B.

[0030] In some preferred embodiments, in the above step 1), the gadoteridol compound crystalline form A is placed in a room under a humidity condition of 40-60% RH for 1 day.

[0031] In some preferred embodiments, the ether organic solvent in step 2) is methyl tert-butyl ether, diphenyl ether, anisole, n-propyl tert-butyl ether and a mixture of two or more thereof, more preferably methyl tert-butyl ether.

[0032] In some preferred embodiments, the ester organic solvent in step 2) is ethyl acetate, isopropyl acetate, butyl acetate, ethyl benzoate, and a mixture of two or more thereof, more preferably ethyl acetate.

[0033] The present invention also exemplarily lists a method for preparing a gadoteridol compound, which comprises the following steps:

[0034]

[0035] As described herein, the new crystal form can be identified by powder X-ray diffraction. However, it is well known to those skilled in the art that the peak intensity and / or peak state of powder X-ray diffraction may vary due to different experimental conditions, such as different diffraction test conditions and / or orientation priority. At the same time, due to the different accuracy of different instruments, the measured 2 θ The value will have an error of about ±0.2°. However, it is known that the relative intensity value of the peak depends more on certain properties of the sample being measured than the position of the peak, such as the size of the crystals in the sample, the orientation of the crystals and the purity of the material being analyzed, so the displayed peak intensity deviation is about ±20% or more. However, despite the existence of experimental errors, instrument errors and orientation preferences, those skilled in the art can still obtain sufficient information for identifying the crystal form from the XRD data provided by this patent.

[0036] In the present invention, "having about Figure 1 "X-ray powder diffraction pattern" or "having about Figure 2 The "X-ray powder diffraction pattern shown" refers to the X-ray powder diffraction pattern showing the main peaks such as Figure 1 or Figure 2 As shown, the main peak refers to Figure 1 or Figure 2 The peaks having relative intensity values ​​exceeding 10%, preferably exceeding 30%, are selected from the group consisting of the highest peak in the graph (whose relative intensity is assigned as 100%).

[0037] In the present invention, when XRD is used for crystal characterization, the instruments and detection parameters used are shown in Table 3.

[0038] Table 3

[0039]

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] The gadoteridol compound crystal form B of the present invention has been subjected to stability test research, and the purity has not been reduced, and there is no obvious difference in the comparison of X-ray diffraction patterns, indicating that the gadoteridol compound crystal form B has good stability and reproducibility, is convenient for the storage of raw materials and the development of preparations, and can meet the needs of drug production. In addition, the present invention provides a crystal preparation method of a gadoteridol compound different from the prior art, with significant process purification effect and suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 : XRD pattern of gadoteridol compound form B.

[0043] Figure 2 : XRD pattern of gadoteridol compound crystalline form A.

[0044] Figure 3 : XRD comparison spectra of gadoteridol compound crystal form A under different stability conditions. From bottom to top,

[0045] line The meanings are as follows:

[0046] XRD spectrum of gadoteridol compound crystal form A obtained by XRD test on day 0;

[0047] The XRD spectrum of the gadoteridol compound crystal form A obtained by XRD testing after drying at 80°C for 24 hours;

[0048] XRD spectrum of the gadoteridol compound crystal form A after being placed at 25°C and 60% RH for 10 days and then subjected to XRD testing;

[0049] The XRD spectrum of the gadoteridol compound crystal form A obtained by performing XRD testing after being placed at 40° C. and 75% RH for 10 days.

[0050] Figure 4 : XRD comparison spectra of gadoteridol compound crystal form B under different stability conditions. From bottom to top, the line The meanings are as follows:

[0051] XRD spectrum of gadoteridol compound crystal form B obtained by XRD test on day 0;

[0052] The XRD spectrum of the gadoteridol compound crystal form B obtained by XRD testing after drying at 80°C for 24 hours;

[0053] XRD spectrum of gadoteridol compound crystal form B after XRD test at 25°C and 60% RH for 10 days;

[0054] XRD spectrum of the gadoteridol compound crystal form B obtained by XRD testing after being placed at 40° C. and 75% RH for 10 days.

[0055] Figure 5 : HPLC spectrum of accelerated stability test of gadoteridol compound crystal form A in 0 month.

[0056] Figure 6 : HPLC spectrum of the accelerated stability test of gadoteridol compound crystal form A for 3 months.

[0057] Figure 7 : HPLC spectrum of the accelerated stability test of gadoteridol compound crystal form A in June.

[0058] Figure 8 : HPLC spectrum of the accelerated stability test of gadoteridol compound crystal form B in 0 month.

[0059] Fig. 9 : HPLC spectrum of the accelerated stability test of gadoteridol compound form B for 3 months.

[0060] Fig.10 : HPLC spectrum of the accelerated stability test of gadoteridol compound form B in June. DETAILED DESCRIPTION

[0061] In order to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with specific embodiments. The embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0062] Example 1 Synthesis of Gadoterol Compounds

[0063]

[0064] Synthesis of Compounds of Formula II

[0065] Add 9.37 kg of N, N-dimethylacetamide, 1.00 kg of the compound of formula I, and 1.91 kg of anhydrous sodium acetate to the reactor, start stirring and cool to -10-20 ° C, and add 4.53 kg of tert-butyl bromoacetate dropwise. After the addition, raise the temperature to 25-35 ° C for insulation reaction. After the reaction is completed, add water to quench the reaction. After stirring, centrifuge and filter, rinse with water, and put the wet product into 50-60 ° C vacuum drying to obtain 2.72 kg of intermediate compound II, with a yield of 79.0%.

[0066] Synthesis of compound of formula III

[0067] 24.00 kg of purified water and 3.00 kg of the compound of formula II were added to the reactor in sequence, the temperature was controlled at 15-25° C., 3.6 L of 10% sodium hydroxide solution was added dropwise, and after the reaction was completed, centrifugation was performed to obtain the compound of formula III.

[0068] Synthesis of Compounds of Formula IV

[0069] The obtained compound of formula III was dissolved in 18.9 kg of ethanol solution, 0.8 kg of sodium hydroxide was added, and the temperature was raised to 55-65° C. After the reaction was completed, centrifugal drying was performed to obtain 2.02 kg of compound of formula IV.

[0070] Synthesis of the gadoteridol compound of formula VI

[0071] 2.00 kg of the compound of formula IV, 6.00 kg of purified water and 0.56 kg of propylene oxide were added to the reactor in sequence, and reacted at 15-25° C. After the reaction was completed, the reaction was concentrated under reduced pressure, and then 260.44 kg of hydrochloric acid and 1.08 kg of gadolinium oxide were added and heated to 70-90° C. for reaction. After the reaction was completed, the reaction was cooled and filtered. The resulting solution was purified and desalted with a cationic resin and an anionic resin, and then concentrated under reduced pressure to obtain 1.98 kg of a crude gadoteridol compound of formula VI with a yield of 73%.

[0072] Example 2 Preparation of Gadoterol Compound Crystalline Form A

[0073] Add 1.00 kg of crude gadoteridol compound, 0.9 kg of purified water, and 0.79 kg of isopropanol to the reactor, heat to 70-80 ° C and stir, then cool to 20-40 ° C to filter the reactants, rinse the filter cake with isopropanol, and place it in a vacuum dryer at 30-40 ° C to obtain the compound crystal form A. The XRD spectrum is as follows Figure 2 .

[0074] Example 3-6 Preparation of Gadoterol Compound Crystalline Form B

[0075] 100 g of gadoteridol compound crystal form A was placed in a room at 40-60% RH for 24 hours, then added to a mixed solution of 90 g of an ether organic solvent and 83 g of an ester organic solvent, dissolved by ultrasound at 40-50° C. to form a clear solution, filtered, stirred at 5-10° C. to precipitate a solid, and then dried in vacuum at room temperature to obtain crystal B. The XRD spectrum is as follows: Figure 1 , as shown in Table 4 below.

[0076] Table 4

[0077] Example Ether organic solvents Ester organic solvent Yield 3 Methyl tert-butyl ether Ethyl acetate 95% 4 n-Propyl tert-butyl ether Butyl acetate 91% 5 Anisole Isopropyl acetate 88% 6 Diphenyl ether Ethyl benzoate 84%

[0078] Example 4 Determination of Crystal Stability

[0079] The gadoteridol compound crystal form A and the gadoteridol compound crystal form B were dried and placed at 80°C for 24 hours, 25°C, 60% RH for 10 days, and 40°C, 75% RH for 10 days. The XRD comparison spectra of the gadoteridol compound crystal form A are shown in FIG. Figure 3 The XRD comparison spectrum of the gadoteridol compound crystal form B is shown in Figure 4 , the comparison results are shown in Table 5 below.

[0080] Table 5

[0081] Crystalline form of gadoteridol compound Dry at 80℃ for 24 hours 25℃, 60%RH for 10 days 40℃, 75%RH for 10 days Crystalline Form A XRD unchanged XRD changes XRD changes Crystalline Form B XRD unchanged XRD unchanged XRD unchanged

[0082] XRD comparison of gadoteridol compound form B under different stability conditions is shown in the attached figure. Figure 4 As shown in the figure, it can be seen that the crystal form B of the gadoteridol compound remains unchanged after being dried at 80°C for 24 hours, 25°C, 60% RH for 10 days, and 40°C, 75% RH for 10 days, and the crystal form B of the gadoteridol compound has good stability. However, the crystal form A changes after being placed at 25°C, 60% RH for 10 days and 40°C, 75% RH for 10 days. When the changed crystal form is placed in a mixed solution of ethers and esters, the gadoteridol compound crystal form B will be obtained again.

[0083] Example 5 Accelerated Test Stability Study of Crystal Form

[0084] The samples of gadoteridol compound crystalline form A and gadoteridol compound crystalline form B were placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months, and samples were taken at 0 month, 3 months and 6 months for HPLC determination. The detection method was as follows: according to the high performance liquid chromatography method, Supelcosil (250mm*4.6mm3.0um) was used as the chromatographic column; the mobile phase was potassium dihydrogen phosphate and potassium dihydrogen phosphate buffer solution-acetonitrile (98:2), a fluorescence detector was used, the excitation wavelength was 275nm; the emission wavelength was 314nm, the flow rate was 1ml per minute, the injection volume was 50ul, and the elution was isocratic.

[0085] According to the HPLC detection method provided above, the final crystallized gadoteridol compound crystal form is used as the test sample, and the content of the gadoteridol compound and the content of the generated impurities can be detected. The HPLC spectra of the gadoteridol compound crystal form A in the accelerated test stability study at 0 month, 3 months and 6 months are shown respectively. Figure 5 , Figure 6 and Figure 7 The HPLC spectra of the accelerated stability test of the gadoteridol compound crystal form B in October, March and June are shown in Figure 8 , Fig. 9 and Fig.10 The corresponding test results and comparison data are shown in Table 6 below.

[0086] Table 6

[0087]

[0088]

[0089] From the data in Table 6, it can be seen that the impurity content of the gadoteridol compound crystal form A increased during the storage process, and the total impurity content reached 1.06% at 6 months, while no impurities were generated during the storage process of the gadoteridol compound crystal form B. It can be seen that compared with the gadoteridol compound crystal form A, the stability of the gadoteridol compound crystal form B has a very significant advantage, and the purification effect of the gadoteridol compound crystal form B is better.

[0090] Example 6 Crystalline Solubility Determination

[0091] The solubility test was conducted on the gadoteridol compound crystal form A and the gadoteridol compound crystal form B. They were placed at room temperature and the solubility results in water are shown in Table 7.

[0092] Table 7

[0093] Crystalline form of gadoteridol compound Solubility in water at room temperature Solubility Classification Crystalline Form A 40-60 mg / mL Dissolve Crystalline Form B 200-300mg / mL Soluble

[0094] It can be seen that different crystal forms of gadoteridol compounds have a great influence on their solubility, and gadoteridol compound crystal form B exhibits outstanding solubility. The classification standard of solubility follows the relevant provisions in the four general rules of the 2020 edition of the Chinese Pharmacopoeia.

Claims

1. A method for preparing a crystalline form B of a gadoteridol compound of formula (VI), characterized in that: The following steps are involved: (1) adding the crude product of the gadoteridol compound to a mixed solution of water and isopropanol, heating to 70-80° C. and stirring, then cooling to 20-40° C. and filtering the reactant, then rinsing the filter cake with isopropanol, and drying it in a vacuum at 30-40° C.; (2) the gadoteridol compound obtained in step (1) is placed at 20-40° C. and 30-90% RH for 0.5-10 days; (3) the gadoteridol compound obtained in step (2) is dissolved in a mixed organic solvent of ethers and esters, ultrasonically dissolved at 40-50° C. to form a clear solution, filtered, stirred at 5-10° C. to precipitate a solid, and dried under vacuum at room temperature to obtain the gadoteridol compound crystal form B; The X-ray powder diffraction spectrum of the crystal form B has a diffraction angle of 2 θ The characteristic peaks are 7.941°, 8.58°, 8.921°, 10.038°, 10.962°, 11.279°, 11.66°, 12.502°, 13.042°, 13.558°, 13.922°, 14.099°, 14.38°, 14.777°, 16.024°, 16.522°, 16.718°, 17.862°, 23.763°, 24.159°, 25.459°, 26.665°, 27.183°, and 30.804°, among which 2 θ The value error range is ±0.2°, 2. The preparation method according to claim 1, characterized in that: The crystal form B has an X-ray powder diffraction pattern as shown in FIG1 .

3. The preparation method according to claim 1, wherein the step (2) is to place the gadoteridol compound obtained in step (1) in a room at a humidity of 40-60% RH for 1 day.

4. The preparation method according to claim 1, wherein the ether organic solvent in step (3) is one or a mixture of more than one of methyl tert-butyl ether, diphenyl ether, anisole, and n-propyl tert-butyl ether.

5. The preparation method according to claim 4, wherein the ether organic solvent in step (3) is methyl tert-butyl ether.

6. The preparation method according to claim 1, wherein the ester organic solvent in step (3) is one or a mixture of more than one of ethyl acetate, isopropyl acetate, butyl acetate, and ethyl benzoate.

7. The preparation method according to claim 6, wherein the ester organic solvent in step (3) is ethyl acetate.